Long-Term Outcomes in Patients With BRAF(V600)-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy: Analysis From Phase 2 and 3 Clinical Trials

BACKGROUND: Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF(V600)-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in thes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Hauschild, Axel, Ascierto, Paolo A., Schadendorf, Dirk, Grob, Jean-Jacques, Ribas, Antoni, Kiecker, Felix, Dutriaux, Caroline, Demidov, Lev V., Lebbé, Céleste, Rutkowski, Piotr, Blank, Christian U., Gutzmer, Ralf, Millward, Michael, Kefford, Richard, Haas, Tomas, D’Amelio, Anthony, Mookerjee, Bijoyesh, Chapman, Paul B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073226/
https://ncbi.nlm.nih.gov/pubmed/31864178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.10.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados